Qiagen NV (QGEN) News & EventsQGENNews & EventsQiagen NV

10x Genomics Awarded $4.8M for Parse Biosciences Infringement

10x Genomics (TXG) announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025. The patents are exclusively licensed from Roche Sequencing Solutions. The jury also rejected Parse's challenges to the validity of the patents, finding all three patents valid and enforceable. "The jury awarded 10x over $4.8M in damages for sales of Parse's infringing Evercode Whole Transcriptome products from February 2021 through June 30, 2026. The damages award is based on a 14% royalty rate on infringing Parse sales. In post-trial proceedings, 10x will seek additional awards including enhanced damages and attorneys' fees for Parse's willful infringement, and a permanent injunction stopping further infringement by Parse in the United States," the company stated. "The evidence presented at trial shows that Parse made a deliberate and calculated decision to ignore Dr. Nolan's seminal inventions in single cell analysis. The jury heard the evidence and soundly rejected Parse's defenses to find that Parse willfully infringed the patents exclusively licensed to Scale. We are pleased with today's verdict, which makes clear that companies cannot simply benefit from the innovation of others and disregard the patent rights protecting them," said Randy Wu, General Counsel of 10x Genomics.

Qiagen Launches QIAsymphony Connect Platform

Qiagen announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction across diverse assay workflows. The platform delivers highly concentrated DNA and RNA for sensitive downstream assays, supporting reliable detection across clinical molecular testing applications including liquid biopsy, oncology and infectious disease diagnostics. "Clinical laboratories need automation solutions that combine proven extraction performance with the standardization, traceability and productivity needed for today's molecular testing workflows," said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at Qiagen. "The commercial launch of QIAsymphony Connect reflects our continued investment in automated sample preparation and strengthens our Sample to Insight portfolio by helping laboratories improve consistency and efficiency across clinical molecular testing." Qiagen has completed the FDA listing in the U.S. and the EUDAMED listing in Europe for QIAsymphony Connect, accomplishing significant regulatory milestones as the platform enters broader commercial availability.

QIAGEN Remains Focused on Delivering Solid Profitable Growth

QIAGEN remains focused on delivering solid profitable growth by advancing its growth pillars, improving operating efficiency and allocating capital to the highest-return opportunities.